XTL Biopharmaceuticals CFO to step down
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Essential IR Insights Newsletter - Summer July-August 2023
Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits
David Kestenbaum plans to cease his services as CFO of XTL Biopharmaceuticals Ltd. and pursue other opportunities.
Kestenbaum will continue working during his notice period, and his successor will be announced in due course.
